cutaneous leishmaniasis cutaneous leishmaniasis meglumine antimoniate co-trimoxazole efficacy
Conditions
Interventions
Participants were randomly allocated to two groups using a lottery method.
Group A: receive I/M injection meglumine antimoniate (15 mg/kg/day) and oral co-trimoxazole.
Patients will attend 2 weekly fo
Active Comparator Drug,Active Comparator Drug
meglumine antimoniate plus co-trimoxazole,meglumine antimoniate
Sponsors
COMBINED MILITARY HOSPITAL QUETTA
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1)Positive LD bodies and confirmation by H/P 2)Patients of both genders 3)Age between15-65 years 4)Multiple lesions on body 5)Lesions on lower legs, over a joint, mucosa or cartilage 6)Lesion(s) > 4 cm in size 7)Lesions not responding to local treatment 8)Lesions that are potentially disfiguring or disabling (i.e. on face, fingers or toes)
Exclusion criteria
Exclusion criteria: 1)Patients who are immunocompromised or with comorbidities (eg. DM, HTN, IHD) 2)People with a known hypersensitivity or allergy to meglumine antimoniate or co-trimoxazole. 3)Pregnant and breastfeeding women 4)Patients enrolled in other research protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical cure by week 12 12 weeks clinical response criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| comparison of efficacy of both groups 12 weeks clinical response criteria | — |
Countries
Pakistan
Contacts
Public Contactrabiya afzaal
COMBINED MILITARY HOSPITAL QUETTA
Outcome results
None listed